Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2014

View Archived Issues

Synergism observed with dabrafenib and trametinib combination in melanoma

Discovery of BRD-3444, a new antimalarial by diversity-oriented synthesis strategy

Novartis cancels launch in Japan of Rasilamlo combination tablets LD and HD

Phase III trial of entinostat begins in advanced breast cancer

Pfizer reports data from phase III study of Xalkori in NSCLC

Med BioGene confirms CLIA approval for GeneFx Lung

Rosetta Genomics collaborates with Clalit Health Services' Rabin Medical Center

Myriad Genetics and Tesaro form HRD companion diagnostic collaboration

Cellceutix initiates trial of Prurisol for psoriasis

PI3K signaling pathway implicated in uterine carcinosarcoma

DMC recommends that COMET-1 study continue to completion

Mologen initiates lung cancer trial of MGN-1703 in Belgium

NIH funds new research consortium for Ebola virus

New PI3K inhibitors disclosed by Roche and Genentech

Janssen R&D Ireland prepares novel compounds for HBV infection

Researchers at Gruenenthal disclose novel calcium channel blockers

Canadian group presents new antibacterial agents

e-Therapeutics recommences patient recruitment in phase I U.K. trial of ETS-2101

LEO-43204 demonstrates efficacy against actinic keratosis in a first-in-human clinical trial

CXD-101 and companion diagnostic studied in new phase I trial

Daiichi Sankyo announces East Asian subgroup analyses from edoxaban trials

Onconova presents in vivo data for ON-146040

Genocea reports updated results from phase I/IIa HSV-2 study of GEN-003

GlaxoSmithKline receives Japanese approval of its nucleic acid analogue for HBV

Albiglutide approved in Europe for type 2 diabetes

FDA accepts NDA for migraine candidate AVP-825

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...